Literature DB >> 20464130

Subcutaneous immunization against Leishmania major - infection in mice: efficacy of formalin-killed promastigotes combined with adjuvants.

Joshua M Mutiso1, John C Macharia, Rosemary M Mutisya, Evans Taracha.   

Abstract

Formalin-killed promastigotes (FKP) of Leishmania major, in combination with Montanide ISA 720 (MISA), BCG or alum were used in vaccination of an inbred murine model against cutaneous leishmaniasis (CL). Significant and specific increases in anti-FKP IgG responses were detected for both alum-FKP and BCG-FKP compared to MISA-FKP (p < 0.001). Significant increases in splenic lymphocyte recall proliferation was obtained in the MISA-FKP vaccinated mice compared to alum-FKP or BCG-FKP vaccinated groups (p < 0.01). The highest interferon-gamma responses were observed in the BCG-FKP group followed by the MISA-FKP while the alum-FKP gave the least responses. Significantly reduced lesion sizes were obtained in the MISA-FKP group compared to the BCG/alum adjuvants-FKP vaccinated groups. Although the BCG-FKP group showed the highest IFN-gamma responses, it failed to control cutaneous lesions. Significant reductions in parasite numbers were observed in the MISA-FKP and BCG-FKP vaccinated groups (p < 0.001). There was a good correlation between parasite burden and IFN-gamma level indicating IFN-gamma response as a sensitive parameter of the immune status. In conclusion, MISA-FKP is the most efficacious vaccine formulation against murine cutaneous leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20464130     DOI: 10.1590/s0036-46652010000200006

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  10 in total

1.  Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.

Authors:  Azam Bolhassani; Martin Muller; Farzin Roohvand; Fatemeh Motevalli; Elnaz Agi; Mehdi Shokri; Mahdieh Motamedi Rad; Sahar Hosseinzadeh
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.

Authors:  Ankita Thakur; Harpreet Kaur; Sukhbir Kaur
Journal:  Med Microbiol Immunol       Date:  2014-11-29       Impact factor: 3.402

3.  Old World cutaneous leishmaniasis: diagnosis and treatment.

Authors:  Abderrahmen Masmoudi; Wala Hariz; Slaheddine Marrekchi; Mariem Amouri; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2013-06-30

4.  Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.

Authors:  María José Germanó; Juan Pablo Mackern-Oberti; Jessica Gardone Vitório; Mariana Costa Duarte; Daniel Carvalho Pimenta; Maria Victoria Sanchez; Flavia Alejandra Bruna; Esteban Sebastián Lozano; Ana Paula Fernandes; Diego Esteban Cargnelutti
Journal:  Front Immunol       Date:  2022-05-12       Impact factor: 8.786

5.  Caffeic acid combined with autoclaved Leishmania major boosted the protection of infected BALB/c mice by enhancing IgG2 production, IFN-γ/TGF-β and iNO synthase/arginase1 ratios, and the death of infected phagocytes.

Authors:  Radia Belkhelfa-Slimani; Bahia Djerdjouri
Journal:  Inflammopharmacology       Date:  2017-10-07       Impact factor: 4.473

Review 6.  In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasis.

Authors:  Samuel W Mwololo; Joshua M Mutiso; John C Macharia; Alain J Bourdichon; Michael M Gicheru
Journal:  J Biomed Res       Date:  2015-03-04

7.  A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo.

Authors:  Zeinab Shirbaghaee; Azam Bolhassani; Abbas Mirshafiey; Fatemeh Motevalli; Negar Zohrei
Journal:  Iran J Cancer Prev       Date:  2015-12-23

8.  The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.

Authors:  Ahmad Mehravaran; Mahmoud Reza Jaafari; Seyed Amir Jalali; Ali Khamesipour; Reza Ranjbar; Mansure Hojatizade; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2016-02       Impact factor: 2.699

9.  A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1-Inclined Immune Response against Visceral Leishmaniasis.

Authors:  Sneha Ratnapriya; Narendra Kumar Yadav; Anuradha Dube; Amogh Anant Sahasrabuddhe
Journal:  Biomed Res Int       Date:  2021-02-27       Impact factor: 3.411

10.  Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Authors:  Joshua Muli Mutiso; John Chege Macharia; Evans Taracha; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.